Combinations Comprising a S1P receptor modulator
AssigneeNovartis AG
InventorsMatthias Meergans, Ferenc Tracik, Katrin Schuh
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination which comprises fingolimod and at least antidepressant compound.
Claims11
Combination which comprises fingolimod in free form, in a pharmaceutically acceptable salt form or as a phosphate derivative, and at least one antidepressant compound or a pharmaceutically acceptable salt thereof and optionally at least one pharmaceutically acceptable carrier;
- for simultaneous, separate or sequential use.
Method of treating depression, in particular in patients affected by multiple sclerosis, comprising administering to a patient in need thereof jointly therapeutically effective amounts of i) fingolimod, in free form, pharmaceutically acceptable salt or phosphate derivative form, and ii) at least one anti-depressive compound in free or pharmaceutically acceptable salt, preferably selected from the group consisting of serotonin-norepinephrine reuptake inhibitor (SNRI) and serotonin reuptake inhibitor (SSRI), or the pharmaceutically acceptable salts of such compounds.
Dependencies are inferred from the claim text.